Propranolol/etodolac

Drug Profile

Propranolol/etodolac

Alternative Names: VT 11CR; VT-122

Latest Information Update: 08 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vicus Therapeutics LLC
  • Developer Vicus Therapeutics
  • Class Indoleacetic acids; Naphthalenes; Nonsteroidal anti-inflammatories; Propanolamines
  • Mechanism of Action Beta-adrenergic receptor antagonists; Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Liver cancer; Prostate cancer
  • Phase I Lung cancer; Solid tumours
  • Clinical Phase Unknown Pancreatic cancer
  • No development reported Cachexia

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 06 Oct 2016 Clinical development is ongoing for Pancreatic cancer (Combination therapy, Metastatic disease) in USA (Vicus Therapeutics pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for clinical development in Pancreatic-cancer(Combination therapy, Metastatic disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top